Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia

Leukemia. 2013 Dec;27(12):2410-3. doi: 10.1038/leu.2013.159. Epub 2013 May 23.

Authors

Q Jiang¹, L-P Xu, D-H Liu, K-Y Liu, R P Gale, M-J Zhang, B Jiang, X-H Zhang, Y Wang, S-S Chen, X-Y Zhao, H Chen, H Jiang, Y-H Chen, W Han, Y-Z Qin, Y-R Liu, Y-Y Lai, M Lv, X-J Huang

Affiliation

¹ Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

PMID: 23698276
DOI: 10.1038/leu.2013.159

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Antineoplastic Agents / therapeutic use*
Benzamides / therapeutic use*
Cohort Studies
Combined Modality Therapy
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Siblings*
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate